The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Open accessAbstract
Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture. Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes. In addition, HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biological processes including cancer initiation and progression. This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–265 of 265
Zhang, L., Zhang, Y., Mehta, A. R., Boufraqech, M., Davis, S. R., Wang, J., Tian, Z., Yu, Z., Boxer, M. B., Kiefer, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3268 · Cited by 61
Zibelman, M. R., Wong, Y., Devarajan, K., Malizzia, L., Corrigan, A., Olszanski, A. J., Denlinger, C. S., Roethke, S. K., Tetzlaff, C. H., & Plimack, E. R. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0261-3 · Cited by 60
Lopez, G., Bill, K. L. J., Bid, H. K., Braggio, D., Constantino, D., Prudner, B., Zewdu, A., Batte, K., Lev, D., & Pollock, R. E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133302 · Cited by 60
Hui, K. F., & Chiang, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28924 · Cited by 60
Koprinarova, M., Botev, P., & Russev, G. C. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.07.003 · Cited by 60
Radhakrishnan, R., Li, Y., Xiang, S., Yuan, F., Yuan, Z., Telles, E., Fang, J., Coppola, D., Shibata, D., Lane, W. S., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612945 · Cited by 60
Self-citationRichardson, P. G. G., Laubach, J. P., Lonial, S., Moreau, P., Yoon, S., Hungria, V. T., Dimopoulos, M. A., Beksaç, M., Alsina, M., & Miguel, J. F. S. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1047770 · Cited by 59
Dual-acting histone deacetylase-topoisomerase I inhibitors
Guerrant, W., Patil, V., Canzoneri, J. C., Yao, L.-P. D., Hood, R., & Oyelere, A. K. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.108 · Cited by 59
Reversible Acetylation Regulates Salt-inducible Kinase (SIK2) and Its Function in Autophagy*
Yang, F.-C., Tan, B. C., Chen, W.-H., Lin, Y.-H., Huang, J.-Y., Chang, H.-Y., Sun, H.-Y., Hsu, P., Liou, G., Shen, J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.431239 · Cited by 58
Lv, Z., Weng, X., Du, C., Zhang, C., Xiao, H., Cai, X., Ye, S., Cheng, J., Ding, C., Xie, H., et al. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22345 · Cited by 57
KAP1 Deacetylation by SIRT1 Promotes Non-Homologous End-Joining Repair
Lin, Y.-H., Yuan, J., Pei, H., Liu, T., Ann, D. K., & Lou, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123935 · Cited by 57
Locatelli, S. L., Cleris, L., Stirparo, G. G., Tartari, S., Saba, E., Pierdominici, M., Malorni, W., Carbone, A., Anichini, A., & Carlo‐Stella, C. (2014) · Leukemia · doi:10.1038/leu.2014.81 · Cited by 57
Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells
Aldana-Masangkay, G. I., Rodrı́guez-González, A., Lin, T. L., Ikeda, A. K., Hsieh, Y., Kim, Y., Lomenick, B., Okemoto, K., Landaw, E. M., Wang, D., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.570821 · Cited by 56
Liu, K., Zhou, D., Ouyang, D., Xu, L., Wang, Y., Wang, L., Pan, H., & He, X. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.007 · Cited by 56
Brunetto, A. T., Ang, J. E., Lal, R., Olmos, D., Molife, L. R., Kristeleit, R. S., Parker, A., Casamayor, I., Olaleye, M., Mais, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0735 · Cited by 56
Saijo, K., Katoh, T., Shimodaira, H., Oda, A., Takahashi, O., & Ishioka, C. (2012) · Cancer Science · doi:10.1111/cas.12002 · Cited by 55
Wang, G., He, J., Zhao, J., Yun, W., Xie, C., Taub, J. W., Azmi, A. S., Mohammad, R. M., Dong, Y., Kong, W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052095 · Cited by 55
Guzmán, M. L., Yang, N., Sharma, K. K., Balys, M. M., Corbett, C. A., Jordan, C. T., Becker, M. W., Steidl, U. G., Abdel-Wahab, O. I., Levine, R. L., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0963 · Cited by 55
Histone deacetylase 1 expression in gastric cancer
Mori, M. (2011) · Oncology Reports · doi:10.3892/or.2011.1361 · Cited by 55
Minamiya, Y., Ono, T., Saito, H., Takahashi, N., Ito, M., Motoyama, S., & Ogawa, J. (2010) · Tumor Biology · doi:10.1007/s13277-010-0066-0 · Cited by 53
Turtoï, A., Mottet, D., Mathéus, N., Dumont, B., Peixoto, P., Hennequière, V., Deroanne, C., Colige, A., Pauw, E. D., Bellahcène, A., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9279-8 · Cited by 53
Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling
Li, S., Liu, X., Chen, X., Zhang, L., & Wang, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-3747-x · Cited by 51
Ray, A., Alalem, M. A., & Ray, B. K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.481184 · Cited by 51
Belinostat for the treatment of peripheral T-cell lymphomas
Jimeno, A., & McDermott, J. D. (2014) · Drugs of today · doi:10.1358/dot.2014.50.5.2138703 · Cited by 51
Halsall, J. A., Turan, N., Wiersma, M., & Turner, B. M. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0021-9 · Cited by 50
Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Newbold, A., Matthews, G. M., Bots, M. L., Cluse, L. A., Clarke, C. J. P., Banks, K.-M., Cullinane, C. M., Bolden, J. E., Christiansen, A. J., Dickins, R. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0626 · Cited by 50
Zorzi, A. P., Bernstein, M. L., Samson, Y., Wall, D. A., Desai, S. J., Nicksy, D., Wainman, N., Eisenhauer, E. A., & Baruchel, S. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24694 · Cited by 50
Juengel, E., Nowaz, S., Makarevi, J., Natsheh, I. Y., Werner, I., Nelson, K., Reiter, M., Tsaur, I., Mani, J., Harder, S., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-152 · Cited by 50
SIRT1 Deacetylates TopBP1 and Modulates Intra-S-Phase Checkpoint and DNA Replication Origin Firing
Wang, R., Lahusen, T. J., Chen, Q., Xu, X., Jenkins, L. M. M., Leo, E., Fu, H., Aladjem, M. I., Pommier, Y. G., Appella, E., et al. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.11066 · Cited by 49
Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with Immunotherapy
Park, J., Thomas, S., & Münster, P. N. (2015) · Epigenomics · doi:10.2217/epi.15.16 · Cited by 47
Wilmott, J. S., Colebatch, A. J., Kakavand, H., Shang, P., Carlino, M. S., Thompson, J. F., Long, G. V., Scolyer, R. A., & Hersey, P. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.34 · Cited by 45
Feng, G.-W., Dong, L.-D., Shang, W.-J., Pang, X.-L., Li, J., Liu, L., & Wang, Y. (2014) · PubMed · Cited by 45
Venza, I., Visalli, M., Oteri, R., Cucinotta, M., Teti, D. V., & Venza, M. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12049 · Cited by 44
Improved Synthesis and Structural Reassignment of MC1568: A Class IIa Selective HDAC Inhibitor
Fleming, C. L., Ashton, T. D., Gaur, V., McGee, S. L., & Pfeffer, F. M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401945k · Cited by 44
Liffers, K., Kolbe, K., Westphal, M., Lamszus, K., & Schulte, A. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0372-y · Cited by 41
Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Jin, Z., Jiang, W., Jiao, F., Guo, Z., Hu, H. X., Wang, L., & Wang, L. (2014) · PubMed · Cited by 41
Saijo, K., Imamura, J., Narita, K., Oda, A., Shimodaira, H., Katoh, T., & Ishioka, C. (2014) · Cancer Science · doi:10.1111/cas.12585 · Cited by 41
Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells
Feng, L., Pan, M., Sun, J., Lu, H., Shen, Q., Zhang, S., Jiang, T., Liu, L., Jin, W., Chen, Y., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0932-x · Cited by 41
Son, C., Keum, J.-H., Yang, K., Nam, J., Kim, M., Kim, S., Kang, C., Oh, S., Kim, C., Park, Y.-S., et al. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-49 · Cited by 41
Bajbouj, K., Mawrin, C., Hartig, R., Schulze‐Luehrmann, J., Wilisch-Neumann, A., Roessner, A., & Schneider‐Stock, R. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0791-2 · Cited by 40
Matsuba, S., Niwa, S., Muraki, K., Kanatsuka, S., Nakazono, Y., Hatano, N., Fujii, M., Zhan, P., Suzuki, T., & Ohya, S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.217315 · Cited by 40
Morschhauser, F., Terriou, L., Coiffier, B., Bachy, E., Varga, A., Kloos, I., Lelièvre, H., Sarry, A.-L., Depil, S., & Ribrag, V. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0206-x · Cited by 39
Macrocyclic Peptoid–Peptide Hybrids as Inhibitors of Class I Histone Deacetylases
Olsen, C. A., Montero, A., Leman, L. J., & Ghadiri, M. R. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300162r · Cited by 39
Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids
Lamblin, M., Dabbas, B., Spingarn, R., Mendoza‐Sanchez, R., Wang, T. T., An, B., Huang, D. C., Kremer, R. B., White, J. H., & Gleason, J. L. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.078 · Cited by 37
Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial
Shi, W., Lawrence, Y. R., Choy, H., Werner‐Wasik, M., Andrews, D. W., Evans, J. J., Judy, K. D., Farrell, C. J., Moshel, Y. A., Berger, A. C., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1433-2 · Cited by 37
Romidepsin for the treatment of T-cell lymphomas
McGraw, A. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120163 · Cited by 35
The Design and Synthesis of a New Class of RTK/HDAC Dual-Targeted Inhibitors
Zhang, X., Su, M., Chen, Y., Li, J. X., & Lu, W. P. (2013) · Molecules · doi:10.3390/molecules18066491 · Cited by 35
Min, S. K., Koh, Y. H., Park, Y., Kim, H. J., Seo, J., Park, H., Cho, S. J., & Kim, I. S. (2012) · Journal of Pathology and Translational Medicine · doi:10.4132/koreanjpathol.2012.46.2.142 · Cited by 35
Beagle, B. R., Nguyen, D. M., Mallya, S., Tang, S. S. K., Lu, M., Zeng, Z., Konopleva, M. Y., Vo, T.-T. T., & Fruman, D. A. (2014) · Oncotarget · doi:10.18632/oncotarget.2992 · Cited by 35
Histone Deacetylase 3 Regulates Cyclin A Stability
Vidal-Laliena, M., Gallastegui, E., Mateo, F., Martínez-Balbás, M., Pujol, M. J., & Bachs, O. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.458323 · Cited by 34
Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
Lee, S. H., Yoo, C., Im, S., Jung, J., Choi, H. J., & Yoo, J. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.8522 · Cited by 34
Sodji, Q. H., Kornacki, J. R., McDonald, J. F., Mrksich, M., & Oyelere, A. K. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.04.014 · Cited by 33
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer
Bilen, M. A., Fu, S., Falchook, G. S., Ng, C. S., Wheler, J. J., Abdelrahim, M., Doğan, B. E., Hong, D. S., Tsimberidou, A. M., Kurzrock, R., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2695-x · Cited by 32
Huang, Z., Peng, S., Knoff, J. S., Lee, S. Y., Yang, B. K., Wu, T.-C., & Hung, C. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-014-0111-1 · Cited by 29
Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells
Ahn, M., AHN, J.-W., Kim, H. S., Lee, J., & Yoon, J. (2015) · Oncology Reports · doi:10.3892/or.2015.3776 · Cited by 28
Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells
Colarossi, L., Memeo, L., Colarossi, C., Aiello, E., Iuppa, A., Espina, V. A., Liotta, L. A., & Mueller, C. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400058 · Cited by 26
Wang, L., Chen, G., Chen, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3149 · Cited by 25
Jazirehi, A. R., Kurdistani, S. K., & Economou, J. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302532 · Cited by 25
de Crémoux, P., Dalvai, M., N’Doye, O., Moutahir, F., Rolland, G., Chouchane-Mlik, O., Assayag, F., Lehmann‐Che, J., Kraus‐Berthier, L., Nicolas, A., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3233-y · Cited by 24
Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer.
Liao, W., Jordaan, G., Srivastava, M. K., Dubinett, S. M., Sharma, S. P., & Sharma, S. (2013) · Europe PMC (PubMed Central) · Cited by 20
Duan, W., Hou, J., Chu, X., Li, X., Zhang, J., Li, J., Xu, W., & Zhang, Y. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.015 · Cited by 20
Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma
Zhou, X., Tolstov, Y. L., Arslan, A., Roth, W., Grüllich, C., Pahernik, S. A., Hohenfellner, M., & Duensing, S. M. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.012 · Cited by 18
Tomosugi, M., Sowa, Y., Yasuda, S., Tanaka, R., Riele, H. T., Ikawa, H., Koyama, M., & Sakai, T. (2012) · Cancer Science · doi:10.1111/cas.12012 · Cited by 11
Kong, H., Tian, S., Kong, Y., Du, G., Zhang, L., Jung, M., Dritschilo, A., & Brown, M. L. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0832-3 · Cited by 10
Resminostat: Opening the door to epigenetic treatments for liver cancer
Zhao, J., & Lawless, M. W. (2015) · Hepatology · doi:10.1002/hep.27853 · Cited by 9
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Self-citationOral squamous cell carcinomas: state of the field and emerging directions
Tan, Y., Wang, Z., Xu, M., Li, B., Huang, Z., Qin, S., Nice, E. C., Tang, J., & Huang, C. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00249-w · Cited by 831
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Aging and age‐related diseases: from mechanisms to therapeutic strategies
Li, Z., Zhang, Z., Ren, Y., Wang, Y., Fang, J., Yue, H., Ma, S., & Guan, F. (2021) · Biogerontology · doi:10.1007/s10522-021-09910-5 · Cited by 640
Fellows, R., Denizot, J., Stellato, C., Cuomo, A., Jain, P., Stoyanova, E., Balázsi, S., Hajnády, Z., Liebert, A., Kazakevych, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02651-5 · Cited by 568
Metadata
- Authors
- Li, Y., & Seto, E.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-09-06
- Volume
- 6
- Issue
- 10
- Pages
- a026831
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2511667040
- Cited by
- 1,284
- References
- 265
- Type
- posted content
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.